---
layout: default
title: Ascorbic Acid
parent: 僅模型預測 (L5)
nav_order: 73
evidence_level: L5
indication_count: 10
---

# Ascorbic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ascorbic Acid: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation

## One-Sentence Summary

Ascorbic acid (Vitamin C) is an essential micronutrient whose best-established clinical role is in preventing and treating vitamin C deficiency (scurvy), with widespread use as a nutritional supplement worldwide.
The TxGNN model predicts it may be effective for **Non-Syndromic Esophageal Malformation**, carrying a prediction score of 99.96%;
however, this direction is currently supported by **0 clinical trials** and **0 publications**, placing it at the lowest evidence level (L5).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Vitamin C deficiency / nutritional supplementation (no India market registration data available) |
| Predicted New Indication | Non-Syndromic Esophageal Malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 — Model prediction only; no supporting studies of any kind |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ascorbic acid is unavailable in this evidence pack. Based on established pharmacology, ascorbic acid (Vitamin C) is an essential water-soluble micronutrient that acts as a cofactor for prolyl and lysyl hydroxylases — enzymes critical to collagen biosynthesis and structural stabilization. It also functions as a potent antioxidant, donating electrons to neutralize reactive oxygen species, and participates in catecholamine synthesis, iron absorption enhancement, and epigenetic regulation via TET enzyme activity.

The TxGNN model's predicted connection to non-syndromic esophageal malformation most likely runs through the pathway of "collagen synthesis → esophageal structural development." In theory, vitamin C is required for adequate collagen crosslinking, which contributes to the mechanical integrity of esophageal tissue walls. A speculative extension of this reasoning might suggest that severe vitamin C deficiency during embryogenesis could impair normal mesenchymal tissue formation.

However, non-syndromic esophageal malformations (including esophageal atresia and tracheoesophageal fistula) are congenital structural defects determined during early embryogenesis, typically arising from disruptions in foregut patterning during weeks 4–6 of gestation. These are not conditions that respond to post-developmental nutritional supplementation, and no epidemiological data links maternal vitamin C deficiency to congenital esophageal anomalies. The mechanistic rationale is highly indirect and insufficient to support further development at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Ascorbic acid currently holds **no drug registrations** in the India market according to available CDSCO data. This likely represents a data gap rather than true unavailability — ascorbic acid is one of the most widely manufactured and distributed generic pharmaceutical compounds globally, available in oral tablet, injectable, effervescent, and chewable formulations in virtually every country.

---

## Safety Considerations

**Drug Interactions** (25 total interactions identified; moderate-level interactions listed first):

| Interacting Drug | Severity | Notes |
|-----------------|----------|-------|
| Amphetamine | Moderate | Ascorbic acid acidifies urine, reducing renal tubular reabsorption of amphetamines and lowering their effect |
| Aluminum hydroxide | Moderate | May reduce gastrointestinal absorption of ascorbic acid |
| Benzphetamine | Moderate | Same urinary acidification mechanism as amphetamine |
| Bortezomib | Moderate | Vitamin C's antioxidant activity may theoretically diminish bortezomib's proteasome-inhibitory efficacy; concurrent use debated in oncology |
| Deferoxamine | Moderate | High-dose vitamin C may enhance iron mobilization and increase deferoxamine-related toxicity in iron-overloaded patients |
| Dextroamphetamine | Moderate | Urinary acidification reduces dextroamphetamine reabsorption |
| Lisdexamfetamine | Moderate | Same mechanism as other amphetamine interactions |
| Metamfetamine | Moderate | Urinary acidification effect |

Minor interactions also identified with: Paclitaxel, Cisplatin, Doxorubicin, Doxorubicin (liposomal), Pseudoephedrine, Ephedrine, Ephedrine (nasal), Ethinylestradiol, Flecainide, Fluphenazine, Indinavir, Mexiletine.

> Full prescribing information including contraindications and boxed warnings should be obtained from the CDSCO package insert, as this data was not available in the current evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Non-syndromic esophageal malformation is a congenital embryonic structural defect with no established or plausible mechanistic link to ascorbic acid. Despite a high TxGNN model score (99.96%), the complete absence of any supporting clinical trials or published literature results in an L5 evidence classification — the lowest tier — making further investment premature.

**To proceed, the following is needed:**

- Establish a biologically plausible mechanistic hypothesis: specifically, whether maternal vitamin C deficiency during early embryogenesis (weeks 4–6) is associated with foregut patterning defects in animal models
- Search medical literature and birth defect registries for any epidemiological signal linking maternal ascorbic acid status to congenital esophageal anomalies
- Retrieve complete MOA data from DrugBank (DB00126) to support or refute any mechanistic hypothesis
- Obtain CDSCO prescribing information to fill the safety data gap (warnings, contraindications)
- Consider whether a zebrafish or rodent developmental model study could generate hypothesis-generating preclinical data before committing further resources
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

